Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Evaluation of glycation gap for clinical use in diabetes management (CROSBI ID 678337)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Krhač, Maja ; Božičević, Sandra ; Stošić Đurić, Darka ; Soldo Jureša, Dragica ; Smirčić Duvnjak, Lea ; Vučić Lovrenčić, Marijana Evaluation of glycation gap for clinical use in diabetes management // Clinica chimica acta / Delanghe, Joris ; Wu, Alan H (ur.). 2019. str. s309-s309 doi: 10.1016/j.cca.2019.03.636

Podaci o odgovornosti

Krhač, Maja ; Božičević, Sandra ; Stošić Đurić, Darka ; Soldo Jureša, Dragica ; Smirčić Duvnjak, Lea ; Vučić Lovrenčić, Marijana

engleski

Evaluation of glycation gap for clinical use in diabetes management

Background-aim. Alternative glycemic markers have recently re-gained interest in diabetes research and clinical care. Considering a substantial interindividual variability assessment of glycemia based exclusively on HbA1c may be insufficient in various clinical circumstances. The concept of glycation gap (GG), defined as the difference between the measured and fructosamine-based predicted HbA1c was proposed as an aid to the assessment of both glycemic control and risk stratification for diabetic complications. The aim of this study was to evaluate fructosamine and GG within HbA1c-based clinical targets in a large cohort of diabetic patients without proteinuria. Methods. Venus blood was collected from 547 consecutive outpatient diabetic patients at their regular checkup. HbA1c and fructosamine were measured with automated immunoturbidimetric and nitrobluetetrazolium colorimetric procedures, respectively (Integra 400Plus, Roche Diagnostics, USA), serum glucose and protein levels with routine methods (AU680 Beckman Coulter, USA). GG was calculated with a previously validated population-derived equation according to Cohen. Patients were divided into three categories of glycemic control according to HbA1c levels: excellent, fair and poor (b49, 49 to 65 and N65 mmol/mol, respectively). Results. A total of 202 patients within the first category had mean fructosamine level 248±30, 78 μmol/L and GG of -4 (95% CI: -6 to -3), those in the second category (N=232) had mean fructosamine 278 ±36, 25 μmol/L and GG was 1 (95% CI: 0 to 3). Patients with poor glycemic control (N=113) had fructosamine level of 342±53, 92 μmol/L while GG was 5 (95% CI: 5 to 9). One-way ANOVA showed a significant increaseof GG values acrosscategories of glycemic control (Pb0, 001). HbA1c and fructosamine were identified as significant determinants of GG (r=0, 4321and -0, 3126, Pb0, 0001) while noinfluence was shown for glucose and protein levels with multiple regression analysis. Conclusions. Poor glycemic control is associated with an increased levels of GG indicating not only high level of blood glucose, but also a disturbed kinetics of glycation. Further studies are needed to evaluate the relationship of GG with clinically established risk factors of diabetic complications.

glycation gap ; diabetes management

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

s309-s309.

2019.

nije evidentirano

objavljeno

10.1016/j.cca.2019.03.636

Podaci o matičnoj publikaciji

Clinica chimica acta

Delanghe, Joris ; Wu, Alan H

Amsterdam: Elsevier

0009-8981

1873-3492

Podaci o skupu

23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB 2019)

poster

19.05.2019-23.05.2019

Barcelona, Španjolska

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost